» Articles » PMID: 16144850

Urinary Endothelin-1 As a Marker of Renal Damage in Sickle Cell Disease

Overview
Date 2005 Sep 8
PMID 16144850
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sickle cell disease (SCD) affects the kidney by acute mechanisms as well as by insidious renal medullary/papillary necrosis, resulting in tubular defects, which increase the risk of dehydration and subsequent sickle crisis. Hypoxia has been reported to stimulate endothelin-1 (ET-1) synthesis by endothelial cells and also in the renal tubule.

Methods: This case-control study measured ET-1 in urine as a marker of its renal synthesis in asymptomatic SCD patients. Baseline plasma and urinary ET-1 levels were measured and followed during a water deprivation study and a subsequent administration of desmopressin.

Results: Urine and plasma levels of ET-1 were elevated in patients with SCD, compared with carefully matched African-French and African controls, and urine ET-1 excretion was associated with a marked urine-concentrating defect. Moreover, urinary ET-1 output was correlated with microalbuminuria in SCD patients.

Conclusions: ET-1 is known to antagonize the tubular effects of vasopressin and to promote renal scarring; increased renal production of ET-1 could produce nephrogenic diabetes insipidus and dehydration in SCD patients through a combination of fibrosis and functional resistance to vasopressin. This study provides a rationale for trials with endothelin receptor antagonists in sickle cell disease nephropathy.

Citing Articles

End Organ Affection in Sickle Cell Disease.

Bathla T, Lotfollahzadeh S, Quisel M, Mehta M, Malikova M, Chitalia V Cells. 2024; 13(11.

PMID: 38891066 PMC: 11174153. DOI: 10.3390/cells13110934.


Sickle Cell Disease and CKD: An Update.

Zahr R, Saraf S Am J Nephrol. 2023; 55(1):56-71.

PMID: 37899028 PMC: 10872505. DOI: 10.1159/000534865.


Endothelin A receptor antagonist attenuated renal iron accumulation in iron overload heme oxygenase-1 knockout mice.

Saurage E, Davis P, Meek R, Pollock D, Kasztan M Can J Physiol Pharmacol. 2022; 100(7):637-650.

PMID: 35413222 PMC: 10164438. DOI: 10.1139/cjpp-2022-0038.


The nephropathy of sickle cell trait and sickle cell disease.

Ataga K, Saraf S, Derebail V Nat Rev Nephrol. 2022; 18(6):361-377.

PMID: 35190716 PMC: 9832386. DOI: 10.1038/s41581-022-00540-9.


Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension.

Al-Qadi M, LeVarge B, Ford H Front Med (Lausanne). 2021; 7:616720.

PMID: 33842491 PMC: 8026868. DOI: 10.3389/fmed.2020.616720.